Phio Pharmaceuticals
PHIO
3 hedge funds and large institutions have $1.85M invested in Phio Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
9% less capital invested
Capital invested by funds: $2.04M → $1.85M (-$194K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$56K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$43K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$25K |
| 4 |
Goldman Sachs
New York
|
-$5K |
| 5 |
PSUF
People's United Financial
Bridgeport,
Connecticut
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
1
Broadfin Capital
New York
| $1.17M | – | – | – |
|
2
Renaissance Technologies
New York
| $342K | – | – | – |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $235K | – | – | – |
|
4
Geode Capital Management
Boston,
Massachusetts
| $63K | – | – | – |
|
|
BIT
5
BlackRock Institutional Trust
San Francisco,
California
| $26K | – | – | – |
|
6
UBS Group
Zurich,
Switzerland
| $5K | – | – | – |
|
|
BFA
7
BlackRock Fund Advisors
San Francisco,
California
| $4K | – | – | – |
|
8
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$25K | – | – |
|
|
10
Goldman Sachs
New York
| – | -$5K | – | – |
|
11
Northern Trust
Chicago,
Illinois
| – | -$3K | – | – |
|
|
PSUF
12
People's United Financial
Bridgeport,
Connecticut
| – | -$4K | – | – |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$56K | – | – |
|
|
TSS
14
Two Sigma Securities
New York
| – | -$4K | – | – |
|
|
VKH
15
Virtu KCG Holdings
New York
| – | -$43K | – | – |
|
PHIO Hedge Fund Activity: Q2 2016 in Review
3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2016, worth a combined $1.85M — down 9.5% from $2.04M a quarter earlier.
Fund positioning in PHIO was balanced in Q2 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Susquehanna International Group, cutting an estimated $56K.
- 3 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $1.85M of Phio Pharmaceuticals stock for Q2 2016, down 9.5% quarter-over-quarter.
- 0 funds opened new Phio Pharmaceuticals positions in Q2 2016 and 0 closed out.
- The largest Phio Pharmaceuticals seller in Q2 2016 was Susquehanna International Group, an estimated $56K sold.
Based on aggregated 13F filings for Q2 2016.